Development of the hemostatic system in the neonate and young infant

Journal of Pediatric Hematology/Oncology

Volumn 12, Issue 1, 1990, Pages 95-104

  Andrew, Maureen ^a   Paes, B ^a   Johnston, M ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Coagulation system; Fibrinolytic system; Hemostatic system; Neonate

Indexed keywords

BLOOD CLOTTING; DEVELOPMENT; DIAGNOSTIC TEST; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFANT; NEWBORN; NORMAL VALUE; REVIEW;

AGING; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFANT, NEWBORN; REFERENCE VALUES; SUPPORT, NON-U.S. GOV'T;

EID: 0025266246     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/00043426-199021000-00019     Document Type: Article

References (67)

1. Johnston M, Zipursky A. Microtechnology for the study of the blood coagulation system in newborn infants. Can J Med Tech 1980;42:159–64.
2. Lammle B, Griffin JH. Formation of the fibrin clot; the balance of procoagulant and inhibitory factors. Clin Haematol 1985;14:281–343.
3. Colman RW, Marder VJ, Salzman EW, Hirsh J. Overview of hemostasis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis; basic principles and clinical practice. Philadelphia: J.B. Lippincott Company, 1987:3–18.
4. Rosenberg RD. Physiology of coagulation; the fluid phase. In: Nathan D, Oski F, eds. Hematology of infancy and child hood, ed 3. Philadelphia: W.B. Saunders Company, 1987:1248–70.
5. Abilgaard U. Purification of two progressive antithrombins of human plasma. Scand J Clin Lab Invest 1967;19:190–5.
6. Fischer AM, Tapon-Bretaudiere J, Bros A, Josso F. Respective roles of antithrombin III and alpha-2-macroglobulin in thrombin inactivation. Thromb Hemostas 1981;45:51–4.
7. Shapiro SS, Anderson DB. Thrombin inhibition in normal plasma. In: Lundblad RL, Fenton JW, Mann KG eds. Chemistry and biology of thrombin. Ann Arbor, MI: Ann Arbor Science Publishing, 1977:361–74.
8. Andrew M, Paes B, Milner R, et al. The development of the human coagulation system in the fullterm infant. Blood 1987;70:165–72.
9. Andrew M, Paes B, Milner R, et al. Development of the coagulation system in the healthy premature infant. Blood 1988;72:1651–7.
10. Forestier F, Daffos F, Galacteros F, et al. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986;20:342–6.
11. Heikenheimo R. Coagulation studies with fetal blood. Biol Neonate 1964;7:319–27.
12. Holmberg L, Henriksson P, Ekelund H, Astedt B. Coagulation in the human fetus, comparison with term newborn infants. J Pediatr 1974;85:860–4.
13. Jensen AH, Josso S, Zamet P, et al. Evolution of blood clotting factors in premature infants during the first 10 days of life; a study of 96 cases with comparison between clinical status and blood clotting factor levels. Pediatr Res 1973; 7:638–44.
14. Bleyer WA, Hakami N, Shepard TH. The development of hemostasis in the human fetus and newborn infant. J Pediatr 1971;79:838–53.
15. Forestier F, Daffos F, Rainaut M, et al. Vitamin K dependent proteins in fetal hemostasis at mid trimester pregnancy. Thromb Haemostas 1985;53:401–3.
16. Toulon P, Rainaut M, Aiach M, et al. Antithrombin III (ATIII) and heparin cofactor II (HCII) in normal human fetuses (21st–27th week). Thromb Haemostas 1986;56:237 (letter).
17. Barnard DR, Simmons MA, Hathaway WE. Coagulation studies in extremely premature infants. Pediatr Res 1979; 13:1330–5.
18. Cade JF, Hirsh J, Martin M. Placental barrier to coagulation factors; its relevance to the coagulation defect at birth and to haemorrhage in the newborn. Br Med J 1969;2:281–3.
19. Andrew M, O’Brodovich H, Mitchell L. The fetal lamb coagulation system during normal birth. Am J Hematol 1988;28:116–8.
20. Kisker CT, Robillard JE, Clark WR. Development of blood coagulation; a fetal lamb model. Pediatr Res 1981;15:1045–50.
21. Mibashan RS, Rodeck CH, Thumpson JK, et al. Plasma assay of fetal factors VIIIc and IX for prenatal diagnosis of haemophilia. Lancet 1979;1:1309–11.
22. Andrew M, Bhogal M, Karpatkin M. Factors XI and XII and prekallikrein in sick and healthy premature infants. N Engl J Med 1981;305:1130–3.
23. Andrew M, Massicotte-Nolan PM, Karpatkin M. Plasma protease inhibitors in premature infants; influence of gestational age, postnatal age and health status. Proc Soc Exp Biol Med 1983;173:495–500.
24. Stefano VD, Leone G, Carolis MPD, et al. Antithrombin III in fullterm and preterm newborn infants; three cases of neonatal diagnosis of ATIII congenital defect. Thromb Haemostas 1987;57:329–31.
25. Shapiro AD, Jacobson LJ, Armon ME, et al. Vitamin K deficiency in the newborn infant; prevalence and perinatal risk factors. J Pediatr 1986;109:675–80.
26. Lane PA, Hathaway WE. Vitamin K deficiency in infancy. J Pediatr 1985;106:351–9.
27. Hathaway WE. ICTH Subcommittee on Neonatal Hemostasis. Thromb Haemostas 1986;55:145.
28. Israels LG, Friesen E, Jansen AH, Israels ED. Vitamin K, increases sister chromatid exchange in vitro in human leukocytes and in vivo in fetal sheep cells; a possible role for “vitamin K deficiency” in the fetus. Pediatr Res 1987; 22:405–8.
29. Schmidt B, Ofosu FA, Mitchell L, et al. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989;25: 405–8.
30. Andrew M, Schmidt B, Mitchell L, et al. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemostas 1990 (in press).
31. Schmidt B, Mitchell L, Ofosu F, Andrew M. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med 1988;112:641–3.
32. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981;10:369–90.
33. Egeberg O. Inherited antithrombin deficiency causing thromphilia. Thromb Diath Haemorrh 1965;13:516–30.
34. Griffin JH, Evatt B, Zimmerman TS, et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981;68:1370–3.
35. Esmon CT. Protein C; biochemistry, physiology, and clinical implications. Blood 1983;62:1155–8.
36. Camp PC, Nixon RR, Cooper R, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984;74:2082–8.
37. Engesser L, Brockmans AW, Briet E, et al. Hereditary protein S deficiency; clinical manifestations. Ann Intern Med 1987;106:677–82.
38. Marciniak E, Wilson HD, Marlar RA. Neonatal purpura fulminans; a genetic disorder related to the absence of protein C in blood. Blood 1985;65:15–20.
39. Branson H, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 1983;ii: 1165–8.
40. Schmidt B, Mitchell L, Ofosu FA, Andrew M. Alpha-2-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma. Thromb Haemostas 1990 (in press).
41. Ganrot PO, Schersten B. Serum alpha-2-macroglobulin concentration and its variation with age and sex. Clin Chim Acta 1967;15:113–20.
42. Andrew M, Mitchell L, Ofosu F. Alpha-2-macroglobulin and antithrombin III are equally important inhibitors of thrombin during childhood. Blood 1988;72:288A.
43. Levine JJ, Udall JN, Evernden BA, et al. Elevated levels of alpha-2-macroglobulin-protease complexes in infants. Biol Neonate 1987;51:149–55.
44. Schmidt B, Buchanan MR, Ofosu F, et al. Antithrombotic properties of heparin in a neonatal piglet model of thrombin induced thrombosis. Thromb Haemostas 1988;60:289–92.
45. Andrew M, Ofosu FA, Schmidt B, et al. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res 1988;52:517–27.
46. Andrew M, Mitchell L, Berry LR, et al. Fibrinogen has a rapid turnover in the healthy newborn lamb. Pediatr Res 1988;23:249–52.
47. Karitysky D, Kleine N, Pringsheim W, Kunzer W. Fibrinogen turnover in the premature infant with and without idiopathic respiratory distress syndrome. Acta Paediatr Scand 1971;60:465–70.
48. Schmidt B, Wais U, Pringsheim W, Kunzer W. Plasma elimination of antithrombin III is accelerated in term newborn infants. Eur J Pediatr 1984;141:225–7.
49. Feusner JH, Slichter SJ, Harker LA. Acquired haemostatic defects in the ill newborn. Br J Haematol 1983;53:73–84.
50. Pencharz PB, Steffee WP, Cochran W, et al. Protein metabolism in human neonates; nitrogen-balance studies, estimated obligatory losses of nitrogen and whole body turnover of nitrogen. Clin Sci Mol Med 1977;52:485–498.
51. Kisker CT, Perlman S, Bohlken D, Wicklund B. Measurements of prothrombin mRNA during gestation and early neonatal development. J Lab Clin Med 1988;112:407–12.
52. Galanakis DK, Mosesson MW. Evaluation of the role of in vivo proteolysis (fibrinogenolysis) in prolonging the thrombin time of human umbilical cord fibrinogen. Blood 1976;48:109–18.
53. Hamulyak K, Nieuwenhuizen W, Devillee PP, Hemker HC. Reevaluation of some properties of fibrinogen purified from cord blood of normal newborns. Throm Res 1983;32:301–20.
54. Witt I, Müller H, Kunter LJ. Evidence for the existence of fetal fibrinogen. Thromb Diath Haemmorrh 1969;22:101–9.
55. Gordon EM, Ratnoff OD, Saito H, et al. Studies on some coagulation factors (Hageman factor, plasma prekallikrein, and high molecular weight kininogen) in the normal newborn. Am J Pediatr Hematol Oncol 1980;2:213–6.
56. Moak B, Frenzel J. Antibody neutralizing material of factor VII during the first weeks of life. Eur J Pediatr 1977;125: 255–8.
57. Manco-Johnson MJ, Marlar R, Hathaway WE. Neonatal protein C; evidence for a dysfunctional protein and for the predisposition to thrombosis (abstr). Thromb Haemostas 1985;54:838.
58. Greffe BS, Manco-Johnson MJ, Marlar RA. Molecular differences in the forms of fetal protein C (abstr). Pediatr Red 1988;23:463A.
59. 4 binding protein from birth to 12 months (abstr). Pediatr Res 1988;23:347A.
60. 4b-BP-bound protein S in human fetuses and fullterm newborns. Thromb Res 1988;49:471–80.
61. 4b-binding protein in neonates. Blood 1988;71:562–72.
62. Bachman F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijen R, Arnout J, eds. Thrombosis and haemostasis. Leuven: Leuven University Press, 1987:227–65.
63. Collen D, Lijnen HR. Fibrinolysis and the control of hemostasis. In: Stamatoyamopoulos G, Nienhuis AW, Leder P, Jaerus PW, eds. The molecular basis of blood diseases. Philadelphia: W.B. Saunders Company, 1987:662–88.
64. Corrigan J. Neonatal thrombosis and the thrombolytic system; pathophysiology and therapy. Am J Pediatr Hematol/Oncol 1988;10:83–91.
65. Estelles A, Aznar J, Gilabert J, Parrilla JJ. Dysfunctional plasminogen in full-term newborns. Pediatr Res 1980;14: 1180–5.
66. Weinstein MJ, Blanchard R, Moake JL, Vosburgh E, Moise K. Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura. Br J Haemotol 1989;72:68–72.
67. Andrew M, Brooker L, Weitz J. Fibrin clot lysis by thrombolytic agents is impaired in the newborn. Thromb Haemostas [abstract] 1989;62:A933.